WS #16550
Iovance Biotherapeutics shares crashed 34% after releasing disappointing Phase 2 data for its non-small-cell lung cancer drug Amtagvi, illustrating the high risk in clinical-stage biotech. Other biotech and medical device firms like Monolithic Power Systems and Establishment Labs are reporting earnings, adding to sector volatility. Investors are increasingly cautious on clinical trials, favoring companies with near-term revenue visibility.
Biotech and Clinical Data Disappointments
Iovance Biotherapeutics shares crashed 34% after releasing disappointing Phase 2 data for its non-small-cell lung cancer drug Amtagvi, illustrating the high risk in clinical-stage biotech. Other biotech and medical device firms like Monolithic Power Systems and Establishment Labs are reporting earnings, adding to sector volatility. Investors are increasingly cautious on clinical trials, favoring companies with near-term revenue visibility.